Ireland - English - HPRA (Health Products Regulatory Authority)

shire pharmaceuticals ireland limited - lanthanum carbonate hydrate - oral powder - 750 milligram(s) - drugs for treatment of hyperkalemia and hyperphosphatemia; lanthanum carbonate

Malta - English - Medicines Authority

shire pharmaceuticals ireland limited block 2 & 3 miesian plaza, 50-58 baggot street lower, dublin 2, ireland - lanthanum - oral powder - lanthanum 750 mg - all other therapeutic products

Malta - English - Medicines Authority

shire pharmaceuticals ireland limited block 2 & 3 miesian plaza, 50-58 baggot street lower, dublin 2, ireland - lanthanum - oral powder - lanthanum 1000 mg - all other therapeutic products

United States - English - NLM (National Library of Medicine)

changzhou pharmaceutical factory - levetiracetam (unii: 44yrr34555) (levetiracetam - unii:44yrr34555) - levetiracetam extended-release tablets are indicated for the treatment of partial-onset seizures in patients 12 years of age and older. levetiracetam extended-release tablets are contraindicated in patients with a hypersensitivity to levetiracetam. reactions have included anaphylaxis and angioedema [see warnings and precautions (5.4)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (aeds), including levetiracetam extended-release tablets, during pregnancy. encourage women who are taking levetiracetam extended-release tablets during pregnancy to enroll in the north american antiepileptic drug (naaed) pregnancy registry by calling 1-888-233­ 2334 or visiting http://www.aedpregnancyregistry.org/. risk summary prolonged experience with levetiracetam in pregnant women has not identified a drug-associated risk of major birth defects or miscarriage, based on published literature, which includes data from pregnancy reg

Ireland - English - HPRA (Health Products Regulatory Authority)

takeda pharmaceuticals international ag ireland branch - lanthanum carbonate hydrate - oral powder - 1000 milligram(s) - drugs for treatment of hyperkalemia and hyperphosphatemia; lanthanum carbonate

Ireland - English - HPRA (Health Products Regulatory Authority)

takeda pharmaceuticals international ag ireland branch - lanthanum carbonate hydrate - oral powder - 750 milligram(s) - drugs for treatment of hyperkalemia and hyperphosphatemia; lanthanum carbonate

United States - English - NLM (National Library of Medicine)

trupharma, llc - levetiracetam (unii: 44yrr34555) (levetiracetam - unii:44yrr34555) - levetiracetam extended-release tablets is indicated as adjunctive therapy in the treatment of partial onset seizures in patients >16 years of age with epilepsy. none pregnancy category c there are no adequate and well-controlled studies in pregnant women. in animal studies, levetiracetam produced evidence of developmental toxicity, including teratogenic effects, at doses similar to or greater than human therapeutic doses. levetiracetam extended-release tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. oral administration of levetiracetam to female rats throughout pregnancy and lactation led to increased incidences of minor fetal skeletal abnormalities and retarded offspring growth pre- and/or postnatally at doses ≥350 mg/kg/day (approximately equivalent to the maximum recommended human dose of 3000 mg [mrhd] on a mg/m 2 basis) and with increased pup mortality and offspring behavioral alterations at a dose of 1800 mg/kg/day (6 times

Ireland - English - HPRA (Health Products Regulatory Authority)

reckitt benckiser ireland ltd - sodium alginate sodium hydrogen carbonate calcium carbonate - oral powder - milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - levetiracetam - oral solution - 100 milligram(s)/millilitre - other antiepileptics; levetiracetam

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - levetiracetam, quantity: 1000 mg - tablet, film coated - excipient ingredients: maize starch; colloidal anhydrous silica; croscarmellose sodium; povidone; microcrystalline cellulose; purified talc; magnesium stearate; titanium dioxide; macrogol 6000; polyvinyl alcohol; macrogol 3350 - use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation. monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme). add-on therapy in the treatment of primary generalized tonic clonic (pgtc) seizures in adults and children from 4 years of age with idiopathic generalised epilepsy (ige).